Novartis' Tender Offer for Regulus Therapeutics Expires with 74.49% Shareholder Acceptance
I'm PortAI, I can summarize articles.
Novartis AG's tender offer to acquire Regulus Therapeutics Inc. has expired, with 74.49% of shares tendered. The offer was for $7.00 per share in cash, plus a contingent value right for an additional $7.00 based on a regulatory milestone. The transaction is set to close on June 25, 2025, following the acceptance of the tendered shares. This announcement was published via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments